<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="208441">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00374530</url>
  </required_header>
  <id_info>
    <org_study_id>KA-20060026</org_study_id>
    <nct_id>NCT00374530</nct_id>
  </id_info>
  <brief_title>Headache Inducing Characteristics and Possible Changes in Cerebral Blood Flow After Administration of PGE2</brief_title>
  <official_title>Headache Inducing Characteristics and Possible Changes in Cerebral Blood Flow After Administration of PGE2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Headache Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Headache Center</source>
  <brief_summary>
    <textblock>
      Before, during and after intravenous administration of PGE2 we score/measure headache, rCBF,
      blood flow in the middle cerebral artery and diameter of superficial temporal artery and
      correlate that to known pathophysiology of headache to see if PGE2 is involved in headache
      pathophysiology.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double-Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Headache</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>rCBF, blood flow, diameter of STA/RA, HR, BP</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Headache</condition>
  <condition>Migraine</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PGE2</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers

        Exclusion Criteria:

          -  Primary Headache, headache on the day of the investigation, hypertension,
             hypotension, pregnant/nursing, daily intake of medication (except oral
             contraceptives), Cardiovascular or CNS disease, drug/alcohol abuse, psychiatric
             disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Troels Wienecke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Danish Headache Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Danish Headache Center</name>
      <address>
        <city>Glostrup</city>
        <zip>DK-2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <lastchanged_date>July 31, 2007</lastchanged_date>
  <firstreceived_date>September 8, 2006</firstreceived_date>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dinoprostone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
